TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00503581

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00853255

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Live Influenza A Vaccine H7N3 (6-2) AA ca Recombinant (A/chicken/British Columbia/CN-6/2004 x A/Ann Arbor/6/60 ca)
Description: Vaccine administered by nasal spray
Study: NCT03628560

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ROBD Step-Wise desaturation sequence
Description: Blood carbon dioxide is controlled at normal or lower value by subject's own breathing rate.
Study: NCT02702869

Intervention type: PROCEDURE
Intervention: LeFort-1 maxillary repositioning

Intervention type: PROCEDURE
Intervention: rhinoplasty

Intervention type: PROCEDURE
Intervention: rhinoplasty

Intervention type: PROCEDURE
Intervention: rhinoplasty

Intervention type: PROCEDURE
Intervention: rhinoplasty
Study: NCT02551224

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient preference questionnaire
Description: The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patient preference questionnaire
Description: The primary variable will be the mean score of questions 1(a) to 1(c) from the preference questionnaire completed at the end of study.
Study: NCT02702869

Intervention type: PROCEDURE
Intervention: myringotomy and tympanostomy tube placement

Intervention type: PROCEDURE
Intervention: myringotomy and tympanostomy tube placement

Intervention type: PROCEDURE
Intervention: myringotomy and tympanostomy tube placement

Intervention type: OTHER
Intervention: speech therapy

Intervention type: OTHER
Intervention: speech therapy

Intervention type: OTHER
Intervention: speech therapy

Intervention type: OTHER
Intervention: speech therapy

Intervention type: OTHER
Intervention: speech therapy

Intervention type: PROCEDURE
Intervention: orthodontia

Intervention type: PROCEDURE
Intervention: orthodontia

Intervention type: PROCEDURE
Intervention: orthodontia

Intervention type: PROCEDURE
Intervention: orthodontia

Intervention type: PROCEDURE
Intervention: presurgical orthopedics

Intervention type: PROCEDURE
Intervention: presurgical orthopedics

Intervention type: PROCEDURE
Intervention: presurgical orthopedics

Intervention type: PROCEDURE
Intervention: presurgical orthopedics

Intervention type: DEVICE
Intervention: sound amplification for hearing
Study: NCT00503581

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Megestrol Acetate
Description: given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT02702869

Intervention type: DEVICE
Intervention: sound amplification for hearing

Intervention type: DEVICE
Intervention: sound amplification for hearing
Study: NCT00503581

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: undergo hysterectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Therapeutic Conventional Surgery
Description: undergo hysterectomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic Conventional Surgery
Description: undergo hysterectomy
Study: NCT01364558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: Diazepam will be administered as a 5 mg dose given IV. The two nasal formulations will be given as a 10 mg dose.
Study: NCT04134468

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegvorhyaluronidase alfa
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abraxane
Description: IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: IV infusion
Study: NCT02117648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Description: Administered orally
Study: NCT02637752

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle counseling or nutrition/physical counselling
Description: A brief (5-10 minute) counseling session for caregivers of the intervention group aimed to encourage an increase in the child's physical activity and decrease sugar-sweetened beverage consumption and screen time. Additionally, the caregivers of the intervention group were provided with the following handouts: five steps to a healthy body weight for teens; beverages; physical activity tips for children 5-11 years; Canadian physical activity guidelines for children 5-11; and Canadian sedentary behavior guidelines for children 5-11.
Study: NCT03931408

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin Sulfate
Description: Gentamicin will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.
Study: NCT01364558

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diazepam
Description: IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
Study: NCT03931408

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo instillation (saline alone)
Description: Saline will be compounded for immediate use in single-dose, disposable BD 50ml Luer-Lok tip syringes. The container closure system for the diluted gentamicin sulfate solution and saline solution will be sterile and processed with depyrogenation. The solution will be slowly infused into the bladder after drainage of urine is complete. While monitoring blood pressure, the solution will remain in the participant's bladder for a least 30 minutes (unless the participant is experiencing autonomic dysreflexia, and in that case, immediately drained) with the goal of attaining 2 hours.

Intervention type: OTHER
Group type: OTHER
Intervention: No instillation
Description: Participants will not receive an instillation of gentamicin or saline alone, but instead will continue standard of care. Participants will be assessed at the pre-, mid- and post-intervention time points.
Study: NCT04644068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor
Study: NCT03516591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMV564 14-Day CIV
Description: A 14-Day Continuous Intravenous Infusion regimen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMV564 14-Day CIV
Description: A 14-Day Continuous Intravenous Infusion regimen
Study: NCT01813591

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: H.P. Acthar Gel
Description: Acthar (40IU or 80IU) given subcutaneously for 5 days in the 1st week, followed by every other day (3 times per week for the next 3 weeks)
Study: NCT02600702

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Siriraj knee exercise
Description: Siriraj knee exercise, 12 position of exercise protocol

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Siriraj knee exercise
Description: Siriraj knee exercise, 12 position of exercise protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical modalities
Study: NCT04173078

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Computerized Distress Intolerance Intervention

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Computerized Healthy Behaviors Intervention
Study: NCT00002602

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Description: 3 dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Description: 3 dimensional conformal radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D-CRT
Description: 3 dimensional conformal radiation therapy
Study: NCT00686660

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cycling, walking
Description: In training period, patients do cycling on cycle ergometry. two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community. four days per week,18 weeks per non-training period, two non-training period per year, two years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: cycling, non-walking
Description: In training period, patients do cycling. two times a week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't receive walk training.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: walking, walking
Description: In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients do walking at community, four days per week, 18 weeks per non-training period, two non-training period per year, two years.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: walking, non-walking
Description: In training period, patients do walking at hospital, two times per week, 8 weeks per training period, two training period per year, two years.~In non-training period, patients don't walking at community.
Study: NCT01364558

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diazepam
Description: IV diazepam will be given as a 5 mg dose. The two nasal formulations will be given as 10 mg doses.
Study: NCT03656328

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Lactobacillus Reuteri 4659
Description: supplementation with L. reuteri 4659 twice a day for 10 days during the standard antibiotic therapy

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: supplementation with a Placebo capsule twice a day for 10 days during the standard antibiotic therapy
Study: NCT01887873

Intervention type: DEVICE
Group type: OTHER
Intervention: Hyaluronan Thiomer i.o. implant
Study: NCT04644068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5305
Description: Oral PARP inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Anti-microtubule agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: IV Anti-microtubule agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: IV Platinum chemotherapeutic

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: T- Dxd
Description: IV Antibody-drug conjugate
Study: NCT02608710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 4.5 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 6 mg
Study: NCT04876066

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Weight-based ketamine dose will be prepared and delivered personally to study physician or study personnel by pharmacy personnel as is done during standard protocol for use of ketamine not part of a clinical study.
Study: NCT03124472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: uterine artery ligation
Description: Uterine artery ligation was performed by grasping the broad ligament with thumb anterior and the index finger lifting the base below the site uterine incision; the uterine artery was singly ligated with No. 1 vicryl suture. Myometrium was included so that uterine vessels are not damaged

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower segment Cesarean section
Description: Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers
Study: NCT04183127

Intervention type: OTHER
Intervention: No intervention
Description: ACPs, qualified or in training, will be invited to participate by email. Interested participants will be provided with study materials and asked to complete an online eligibility questionnaire; if eligible, contact details will also be recorded. Participants will be invited to take part in a focus group about their experience in developing clinical competence and their opinions on role identity. Data collection will consist of focus groups.
Study: NCT02608710

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 6 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 12 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RDEA3170 12 mg
Study: NCT04644068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dato-DXd
Description: IV Antibody-drug conjugate
Study: NCT01896531

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 5-Fluorouracil
Description: Participants will receive bolus and infusional 5-fluorouracil on Day 1 of each 14-day cycle (as a part of mFOLFOX6 therapy), until disease progression or unacceptable toxicity. The infusion times for infusional 5-fluorouracil may be determined per local and/or institutional standards and product labeling.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipatasertib
Description: Participants will receive ipatasertib, 600 milligrams (mg) orally once daily on Days 1 to 7 of each 14-day cycle until disease progression or unacceptable toxicity.
Study: NCT02714426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Brain health
Description: Eight weekly group brain health sessions lasting 90-120 minutes. The intervention is psychoeducational, and each week presents information from NIH regarding factors that may promote cognitive health in late life (e.g., sleep, physical activity, social engagement and leisure, cognitive training). Weekly sessions are supplemented with educational videos and group discussion. Weekly homework consists of readings about brain health.
Study: NCT02529215

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Just-in-time training (JITT)
Description: The JITT training is a 20 minute simulation-based teaching session targeting: (1) CPR quality and (2) medication administration.
Study: NCT00603837

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NeoWrap
Description: This is a polyethylene wrap that will be placed around the ELGAN from the neck down to prevent heat loss.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InfaTherm
Description: A gel blanket containing a sodium acetate-based medium that, when activated, becomes exothermic and provides heat.
Study: NCT02485119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY94-9343
Description: Cohort 1: 4.5 mg/kg of BAY 94-9343 at Q3W dose regimen. Cohort 2: 6.5 mg/kg of BAY 94-9343 at Q3W dose regimen.
Study: NCT03124472

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Lower segment Cesarean section
Description: Pfannenstiel incision of skin and opening of the anterior abdominal wall in layers.~- The loose peritoneum of the lower uterine segment is dissected downwards to mobilize the urinary bladder and expose the lower uterine segment.~Cresenteric lower uterine segment incision was performed as usual. Higher incisions were performed in cases where the traditional incision was expected to be directly through the placenta Delivery of the baby and placenta.~* Closure of the uterine incision in 2 layers with N0. 1 vicryl suture.~* Closure of the anterior abdominal wall in layers
Study: NCT03703414

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal microbiota composition analysis and blood cytokine level analysis
Description: Fecal microbiota composition analysis and blood cytokine level analysis

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal microbiota composition analysis and blood cytokine level analysis
Description: Fecal microbiota composition analysis and blood cytokine level analysis
Study: NCT02429557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal compression
Description: Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Abdominal compression
Description: Abdominal compression of 40 mmHg with a commercial inflatable cuff applied during head up tilt
Study: NCT03703414

Intervention type: DIAGNOSTIC_TEST
Intervention: Fecal microbiota composition analysis and blood cytokine level analysis
Description: Fecal microbiota composition analysis and blood cytokine level analysis
Study: NCT03461666

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy-Insomnia
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy-Insomnia
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy-Insomnia
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavior Therapy-Insomnia
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus of Attention
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus of Attention
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus of Attention
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Focus of Attention
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined-CBT-I and FOA Group
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.
Study: NCT04644068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camizestrant
Description: Oral SERD Molecule
Study: NCT03461666

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined-CBT-I and FOA Group
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined-CBT-I and FOA Group
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Combined-CBT-I and FOA Group
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Sleep Hygiene
Description: Behavioral Psycho-intervention education therapy.Face to Face, Six sessions, one hour each.